Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 16/20 | 0.60 |
| ▸ | MET | P08581 | 4/20 | 0.60 |
| ▸ | KDR | P35968 | 3/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | RET | P07949 | 2/20 | 0.56 |
| ▸ | MERTK | Q12866 | 2/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | TEK | Q02763 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29487165 | 1.00 | AXL (0.60) | AXLMETKDRPDGFRAPDGFRB | |
| SCHEMBL1132352 | 0.90 | AXL (0.55) | AXLMETKDRPDGFRAPDGFRB | |
| SCHEMBL30066135 | 0.90 | AXL (0.55) | AXLMETKDRPDGFRAPDGFRB | |
| SCHEMBL1132195 | 0.89 | AXL (0.62) | AXLMETKDRPDGFRAPDGFRB | |
| SCHEMBL21083204 | 0.89 | KDR (0.57) | AXLMETKDRPDGFRAPDGFRB | |
| SCHEMBL1132368 | 0.88 | AXL (0.51) | AXLMETKDRPDGFRAPDGFRB | |
| SCHEMBL1132845 | 0.87 | AXL (0.55) | AXLMETKDRPDGFRAPDGFRB | |
| SCHEMBL22960013 | 0.86 | AXL (0.51) | AXLMETKDRPDGFRAPDGFRB | |
| SCHEMBL29487144 | 0.86 | AXL (0.51) | AXLMETKDRPDGFRAPDGFRB | |
| SCHEMBL1890635 | 0.85 | AXL (0.65) | AXLMETKDRPDGFRAPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107889-A1 | PROCESS FOR PRODUCING ACYLTHIOUREA COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-04-06 | — | — | US | claimed |
| EP-4105200-A1 | METHOD FOR PRODUCING ACYLTHIOUREA COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-12-21 | — | — | EP | claimed |
| WO-2021162097-A1 | ANALOGOUS SUBSTANCES OF ACYL THIOUREA COMPOUND | 大鵬薬品工業株式会社 | 2021-08-19 | — | — | WO | claimed |
| EP-4647127-A2 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12371428-B2 | Pyridone compounds and methods of use | EXELIXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-3743070-B1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-117820226-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117624045-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117603138-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2024-02-08 | — | — | US | disclosed |
| CN-117402114-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-111757735-A | Compounds for the treatment of kinase-dependent disorders | 埃克塞里艾克西斯公司 | 2020-10-09 | — | — | CN | disclosed |
| US-10689361-B2 | Quinoline derivative and use thereof | YIN JIANMING (CN) | 2020-06-23 | — | — | US | disclosed |
| WO-2019148044-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019148044-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-20190169163-A1 | QUINOLINE DERIVATIVE AND USE THEREOF | YIN JIANMING (CN) | 2019-06-06 | — | — | US | disclosed |
| EP-2287155-B1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-8304427-B2 | Acylthiourea compound or salt thereof, and use thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-11-06 | — | — | US | disclosed |
| EP-2287155-A1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE OF THE COMPOUND OR THE SALT | Taiho Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20110034439-A1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034439-A1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF | MET, HGF, STAT6 | AXL 568/4885MET 1/4885KDR 296/4885 |
| US-12371428-B2 | Pyridone compounds and methods of use | PDXK, PLK2, MAP4K2 | AXL 1100/4885MET 2371/4885KDR 2892/4885 |
| US-20190169163-A1 | QUINOLINE DERIVATIVE AND USE THEREOF | KDR, FLT4, FLT1 | AXL 158/4885MET 16/4885KDR 1/4885 |
| US-20230107889-A1 | PROCESS FOR PRODUCING ACYLTHIOUREA COMPOUND | AGPAT2, ACAT2, AADAC | AXL 4077/4885MET 2207/4885KDR 4382/4885 |
| US-10689361-B2 | Quinoline derivative and use thereof | KDR, FLT4, FLT1 | AXL 158/4885MET 16/4885KDR 1/4885 |
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, MAP3K1 | AXL 269/4885MET 154/4885KDR 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.